Skip to main content
Fig. 2 | BMC Pharmacology and Toxicology

Fig. 2

From: The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia

Fig. 2

(a) Response rate and (b) control rate of sitting systolic blood pressure (siSBP), and (c) goal attainment rate of low-density lipoprotein cholesterol (LDL-C) by fimasartan 120 mg/rosuvastatin 20 mg (FMS/RSV) treatment, fimasartan 120 mg alone (FMS) treatment, and rosuvastatin 20 mg alone (RSV) treatment at week 8. (Full analysis set)

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us